Clinical Trial Goal
To find out:
- The highest dose of INCA033989 that's safe to give
- If INCA033989, alone or with ruxolitinib, is safe and works well to treat myelofibrosis
You may be able to join this trial if you:
- Are 18 years or older
- Have one of the following diseases:
- Post-essential thrombocythemia myelofibrosis
- Post-polycythemia vera myelofibrosis
- Primary myelofibrosis
- Have not had an allogeneic (cells from a donor) or autologous (your own cells) blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
INCA033989 is a monoclonal antibody that targets CALR in certain cells.
Ruxolitinib is a small molecule inhibitor that blocks JAK1 and JAK2 in certain cells. This means the drug tries to stop certain T-cell signals that can lead to tissue damage.
In this trial, you’ll be placed in 1 of 2 groups:
Ruxolitinib is a small molecule inhibitor that blocks JAK1 and JAK2 in certain cells. This means the drug tries to stop certain T-cell signals that can lead to tissue damage.
In this trial, you’ll be placed in 1 of 2 groups:
- Group 1 – INCA033989
- Group 2 – INCA033989 plus ruxolitinib
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- INCA033989 – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Ruxolitinib - A pill that you take by mouth
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to about 3 years.
The Food and Drug Administration (FDA) has not yet approved INCA033989.
Contacts
Incyte Corporation Call Center (US), 1.855.463.3463, medinfo@incyte.com
Incyte Corporation Call Center (ex-US), +800 00027423, eumedinfo@incyte.com
Locations
Sponsors
lead: Incyte Corporation
